gz-α

Ibiglustat (L-Malic acid) (Ibiglustat L-Malic acid) is a selective, brain-penetrant, and allosteric inhibitor of glucosylceramide synthase. Ibiglustat (L-Malic acid) can be used in studies about PD Parkinson's disease, SRT in Fabry's and Gaucher's.

GZ-793A suppresses dopamine uptake at the vesicular monoamine transporter-2 (VMAT2. A lobelane analog, GZ-793A interacts with the vesicular monoamine transporter-2 to inhibit the effect of methamphetamine.

Ibiglustat (GZ402671) is a potent and selective Glucosylceramide synthase inhibitor and ceramide glucosyltransferase inhibitor. Ibiglustat blocks the formation of glucosylceramide (GL-1), a key intermediate in the synthesis of GL-3. Ibiglustat is potentially useful for treating Fabry disease. Fabry disease is a rare lysosomal storage disorder, which results in abnormal tissue deposits of a particular fatty substance called globotriaosylceramide (GL-3 or Gb3) throughout the body.

GZ-11608, a selective and potent inhibitor of vesicular monoamine transporter-2 (VMAT2), presents a high affinity with a Ki value of 25 nM. It effectively reduces dopamine release induced by methamphetamine from isolated synaptic vesicles in brain dopaminergic neurons. GZ-11608 also demonstrates rapid penetration into the brain without exhibiting neurotoxicity, making it a valuable compound for researching methamphetamine use disorder [1].

Ligustrazine (Tetramethylpyrazine), a natural compound isolated from Chinese herbal medicine Ligusticum wallichii (Chuan Xiong) shows anti-inflammation, antioxidant, antiplatelet, and antiapoptosis activities.

Ligustrazine hydrochloride (Chuanxiongzine hydrochloride) is a chemical compound found in natto and in fermented cocoa beans with anti-inflammation, antioxidant, antiplatelet, and antiapoptosis activities.

Trimethylammonium chloride is a product of the breakdown of plants and animals and is a non-competitive acetylcholinesterase inhibitor.

GZD856 is an orally bioavailable PDGFRα/β inhibitor (IC50s: 68.6 and 136.6 nM) with anti-lung cancer activities.

YGZ-331, a sedative hypnotic, acts by elevating GABA levels as a derivative of the adenosine nucleoside NGBA. It functions through activating A1R and A2aR, and inhibiting the phosphorylation of CaMKII (pCaMKII), thereby exerting its calming effects. Additionally, YGZ-331 reduces spontaneous motor activity in mice.

NagZ-IN-1 (Compound 11h) is a β-N-acetylglucosaminidase inhibitor with a Ki of 3.3 μM. It is applicable in antibacterial research, especially for studies related to Pseudomonas aeruginosa infections.

GZNL-P36 is an orally active inhibitor of SARS-CoV-2 papain-like protease (PLpro), with an IC50 of 6.45 nM. It effectively inhibits SARS-CoV and its variants, showing an EC50 ranging from 58.2 nM to 2.66 μM. In CD-1 mouse models, GZNL-P36 reaches a maximum plasma concentration (Cmax) of 549 ng/mL, with a half-life (T1/2) of 1.45 hours and a bioavailability of 74.7%. Additionally, GZNL-P36 exhibits antiviral activity in mice infected with SARS-CoV-2 XXB.1.

Olverembatinib dimesylate (GZD824 Dimesylate) is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I).

GZ4 is a Ca2+ currents inhibitor, acting on cell surface channels.

GZ389988 is a potent Trk inhibitor.

Olverembatinib (GZD 824) is an orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT, IC50: 0.34 nM) and Bcr-Abl(T315I, IC50: 0.68 nM).

Yingzhaosu B is a biochemical.

Ibiglustat (Venglustat) succinate is an orally active, brain-penetrant inhibitor of glucosylceramide synthase (GCS) utilized in the investigation of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease.

1. Glaucocalyxin A (Leukamenin F)-SBE-β-CD could be useful with a better solubility and sustained function in drug delivery. 2. Glaucocalyxin A activates caspase-3, decreases BAD phosphorylation, and reduces the expression of X-linked inhibitor of apoptosis protein. 3. Glaucocalyxin A inhibits Akt phosphorylation, suppresses proliferation, and promotes apoptosis in a dose-dependent manner, but not in normal glial cells. 4. Glaucocalyxin A inhibits collagen-stimulated tyrosine phosphorylation of Syk, LAT, and phospholipase Cγ2, the signaling events in collagen receptor GPⅥ pathway. 5. Glaucocalyxin A could potentially be developed as an antiplatelet and antithrombotic agent, can inhibit platelet p-selectin secretion and integrin activation by convulxin, is a GPVI selective ligand.

GZD856 formic is a potent, orally active inhibitor of PDGFRα/β and Bcr-Abl T315I, demonstrating IC50 values of 68.6 nM and 136.6 nM for PDGFRα/β, respectively, and 19.9 nM and 15.4 nM for native Bcr-Abl and the T315I mutant, respectively. This compound exhibits significant antitumor activity.

Boc-Arg(Z)2-OH is an amino acid derivative and has a wide range of applications in life science related research.

GZN39838, also known as 6beta-Acetoxy-7alpha-hydroxyroyleanone is a natural blocker of Kv1.2 channels, not involving direct occlusion of the outer pore but depending on C-type inactivation.

Jingzhaotoxin-V, a 29-residue polypeptide from Chilobrachys jingzhao spider venom, selectively inhibits tetrodotoxin-resistant and tetrodotoxin-sensitive sodium currents in rat dorsal root ganglion neurons, with IC50 values of 27.6 nM and 30.2 nM, respectively. Furthermore, it suppresses Kv4.2 potassium currents in Xenopus laevis oocytes, with an IC50 of 604.2 nM [1].

Jingzhaotoxin-IX is a C-terminally amidated peptide neurotoxin consisting of 35 amino acid residues. It inhibits both tetrodotoxin-resistant and tetrodotoxin-sensitive isoforms of voltage-gated sodium channels, as well as the Kv2.1 channel. However, Jingzhaotoxin-IX does not affect the delayed rectifier potassium channels Kv1.1, Kv1.2, and Kv1.3 [1].

Jingzhaotoxin-II, a neurotoxin composed of 32 amino acid residues featuring two acidic and two basic residues, selectively inhibits voltage-gated sodium channels (VGSC), notably slowing the rapid inactivation of TTX-resistant (TTX-R) VGSC in cardiac myocytes, with an IC50 of 0.26 μM [1].